Good news about America’s Covid-19 vaccine
Good news about America’s Covid-19 vaccine campaign
There’s genuinely good news on Covid-19: America’s vaccination campaign has improved at a steady clip in the last month, with the US hitting the kinds of numbers it needs to end the country’s outbreak this year, maybe even this summer.
According to Our World in Data, the US first breached the weekly average of 1 million doses a day on January 23. Less than three weeks later, on February 11, the country hit 1.6 million a day.
chart, line chart© Our World in Data
This meets both the goals set by President Joe Biden, who initially called for 1 million shots a day and then later revised his goal to 1.5 million shots a day.
That doesn’t mean the US is in the clear. Many experts argued Biden’s goals haven’t been ambitious enough. To get the US to herd immunity — when enough of the US population is immune so the virus no longer poses a major threat — by the end of the summer, America likely needs to hit an average of 2 million or 3 million doses a day.
America’s possible vaccine futures
Gallery: Amazing health news you probably missed due to COVID (Espresso)
a person posing for the camera: If it seems like the past year’s headlines have consisted of nothing but COVID-19, take heart; medical researchers around the world have continued to work on the bigger picture and produced plenty of good news on the health front. Here are some of the breakthroughs you might have missed.
Consider the following possibilities, assuming a herd immunity threshold of 80 percent (which could be too low or too high) and all vaccines continue to require two doses (which seems unlikely now):
At 1.6 million shots a day, the US would reach herd immunity by mid-December.
At 2 million shots a day, the US would reach herd immunity by mid-October.
At 3 million shots a day, the US would reach herd immunity by the end of July.
At 5 million shots a day (woo!), the US would reach herd immunity by the end of May.
There are several things that could speed this all up in the coming months. The Biden administration and drug companies could succeed in pumping out more vaccine doses (which already seems to be happening). Government and private actors could improve their vaccine rollouts to get more shots in arms faster. Other vaccines will almost certainly come to the market that only require one shot — Johnson & Johnson’s one-dose vaccine is already working through the last stage of federal approval.
In other words, the numbers above could be pessimistic.
Still, there are several problems that could slow things down. As vaccine efforts scale up, there could be new supply shortages and bottlenecks that take too long to overcome (as happened with Covid-19 testing). Maybe local and state officials can’t improve their rollouts quickly enough. A vaccine for children may not be approved this year. If enough people resist getting a vaccine, herd immunity could be difficult to reach. Perhaps it turns out the vaccines don’t protect against spread — they’re currently only proven to prevent illness and death — and reaching herd immunity is impossible.
Most alarming to experts: New variants of the coronavirus could arise, even worse than those that have appeared in the UK, South Africa, and Brazil so far. If new variants manage to overcome the current vaccines, they could require at the very least a booster shot — further slowing down the rollout by adding yet another dose — or require producing new vaccines altogether.
Concerns about the new variants are one of the reasons experts are calling for speed. Obviously, speeding up the vaccine rollout saves lives — with more than 2,500 still dying from Covid-19 a day — and gets life back to normal more quickly (hopefully before the next school year). But prolonging the pandemic also increases the risk of another variant: The longer the coronavirus is spreading and replicating within humans, the likelier it is, during its millions of replications, to mutate into a scarier form that widely spreads.
So it’s very welcome news that America’s vaccine rollout has consistently improved over the past few weeks. But that progress needs to continue and even speed up — or the US risks making its Covid-19 outbreak even worse.
https://www.msn.com/en-us/money/news/good-new...d=msedgntp
TOODLES
1
Scroll down for more posts ▼
Top 10 Most Recent News Articles
History's got chapters that stick with you, and the Long March is one of those stories that shake you to your core. It all started one October evening in 1934, when more than 86,000 soldiers from the Red Army found themselves on the banks of the Yudu River. It was a scene straight out of a novel: 800-odd boats held together with coffin boards and timber beams, all set to...
Continue Reading
You know, every now and then, it's worth stepping out of the stock frenzy and diving into something as electrifying and far from the trading floor as Tomorrowland's latest Shanghai rendezvous. This ain't just any festival; it's the kind of hype that packs a punch—and frankly, it's a wild ride seeing such a spectacle set up shop in China, and sell out to boot. Partnering...
Continue Reading
Antheia's Bold Move to Onshore Medicine Production Folks, when it comes to pharmaceuticals, it's about time someone started serious about keeping things closer to home. Antheia just landed a huge $80 million conditional commitment from the U.S. Department of War's Office of Strategic Capital. The fine print? This isn't just about building business—it's a play to secure...
Continue Reading
Breaking Ground with Patient Representation Today's not-so-sunny forecast from Barcelona wasn't about the weather. United European Gastroenterology (UEG) rolled out its shiny new Patient Representatives Advisory Board (PRAB) during UEG Week 2026. This isn't just another committee on a never-ending list—it's a serious platform aimed at turning patient murmurs into a...
Continue Reading
A Fresh Chapter for Lundbeck's Board Leadership Lundbeck is sparking some fresh boardroom energy, and it's not just business as usual. Dorothea Wenzel, who's been steering the ship, is stepping down come 2027—AGM in sight. Now, in swings Lars Fruergaard Jørgensen, ready to grab the wheel. Yeah, we've got some seasoned pharma muscles flexing here. The Before and After:...
Continue Reading
Clock Ticking on AEVEX Lawsuit Participation Ah, the twists and turns of the stock market! AEVEX Corp. (NYSE: AVEX) finds itself knee-deep in a class action lawsuit, and investors have a mere 48 hours left to make their stand as the lead plaintiff. This legal saga stems from the company's April 2026 IPO and spills into the muddy waters of securities law violations....
Continue Reading
AST SpaceMobile's Legal Tangle AST SpaceMobile, Inc. (NASDAQ:ASTS) finds itself neck-deep in legal quagmire, with a class action lawsuit looming large. Investors who snapped up ASTS securities between March 4, 2025, and July 15, 2026, have until November 13, 2026, to reckon their grievances before the courts. This is no joke, folks. If you've lost dough because of shaky...
Continue Reading
Top 5 Most Recently Viewed Articles
Funding That Signals Confidence in AI Monetization The tech world is buzzing, and for a damn good reason. Koah just bagged a hefty $20.5 million in a Series A funding round, led by Theory Ventures. Now before you roll your eyes and think it’s just more Silicon Valley smoke and mirrors, listen up. This isn’t just another pie-in-the-sky idea; it’s about bringing real...
Continue Reading
Support for Genuine Foods' Growth Lafayette Square is excited to announce its recent investment to boost the expansion of Genuine Food Lab, LLC, also known as Genuine Foods. This Boston-based foodservice management company has made it its mission to provide nourishing meals for K-12 schools and higher education institutions across a wide geographic area. About Genuine...
Continue Reading
Minto Apartment REIT Set to Announce Financial Results Minto Apartment Real Estate Investment Trust (the "REIT") (TSX: MI) is making headlines as it prepares to share its third quarter financial results for the year 2025. This upcoming announcement is highly anticipated by investors and analysts alike, as it provides crucial insights into the company's performance and...
Continue Reading
Major Milestone Achieved for Eastern Bankshares and HarborOne Eastern Bankshares, Inc. (NASDAQ: EBC), the parent company of Eastern Bank, and HarborOne Bancorp, Inc. (NASDAQ: HONE), which oversees HarborOne Bank, share exciting news. They have successfully received all the regulatory approvals necessary to finalize their anticipated merger, a strategic move announced...
Continue Reading
Home Flipping Profit Margins Reach Historic Lows The latest report reveals a concerning trend in the home flipping market, with profit margins reaching their lowest level in 17 years. The typical return on investment (ROI) for a flipped home has plummeted to just 25.1 percent as of the second quarter, reflecting broader challenges in the real estate landscape. Current...
Continue Reading